68Ga-BBN-IRDye800CW(68Ga-BBN-IRDye800CW) - 药物靶点：GRPR_在研适应症：胶质母细胞瘤_专利_临床

概要

基本信息

药物类型

多肽偶联核素、诊断用放射药物

别名-

靶点

GRPR

作用机制

GRPR调节剂(胃泌素释放肽前体受体调节剂)、PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症

胶质母细胞瘤

非在研适应症

低级神经胶质瘤

原研机构

National Institute For Biomedical Imaging And Bioengineering (Nibib)

在研机构

中国科学院北京天坛医院National Institute For Biomedical Imaging And Bioengineering (Nibib)

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

3

项与 68Ga-BBN-IRDye800CW 相关的临床试验

NCT05047510 / RecruitingN/AIIT

An Evaluation Study of GPC3 Targeted Fluorescence Imaging to Guide the Surgery of Hepatocellular Carcinoma

This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma.
The main purposes of this study include:
① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore.
② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.

开始日期2021-09-10

申办/合作机构

中国科学院

NCT03407781 / Completed临床1期

IRDye800CW-BBN PET-NIRF in Lower Grade Glioma

This is an open-label positron emission tomography/near infrared (PET/NIRF) study to investigate the imaging navigation performance and evaluation efficacy of dual modality imaging probe 68Ga-BBN-IRDye800CW in patients with lower grade glioma. A single dose of 40μg/111-148 Mega-Becquerel (MBq) 68Ga-NOTA-BBN and 1.0- or 2.0- mg/ml IRDye800CW-BBN will be injected intravenously before the operation and intraoperative respectively. Visual and semiquantitative method will be used to assess the PET images and real-time margins localization for surgical navigation.

开始日期2016-01-01

申办/合作机构

中国科学院

[+2]

NCT02910804 / Unknown status早期临床1期IIT

PET-NIRF Dual Modality Imaging Guiding Surgery in Patients With Glioblastoma

This is an open-label positron emission tomography/near infrared (PET/NIRF) study to investigate the imaging navigation performance and evaluation efficacy of dual modality imaging probe 68Ga-BBN-IRDye800CW in glioblastoma (GBM) patients. A single dose of 40μg/111-148 Mega-Becquerel (MBq) and 1.0 mg/ml 68Ga-BBN-IRDye800CW will be injected intravenously before the operation and intraoperative respectively. Visual and semiquantitative method will be used to assess the PET images and real-time margins localization for surgical navigation.

开始日期2015-11-01

申办/合作机构

北京天坛医院

[+3]

100 项与 68Ga-BBN-IRDye800CW 相关的临床结果

登录后查看更多信息

100 项与 68Ga-BBN-IRDye800CW 相关的转化医学

登录后查看更多信息

100 项与 68Ga-BBN-IRDye800CW 相关的专利（医药）

登录后查看更多信息

100 项与 68Ga-BBN-IRDye800CW 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胶质母细胞瘤	临床1期	-	中国科学院	-
胶质母细胞瘤	临床1期	-	北京天坛医院	-
胶质母细胞瘤	临床1期	-	National Institute For Biomedical Imaging And Bioengineering (Nibib)	-
低级神经胶质瘤	临床前	中国	National Institute For Biomedical Imaging And Bioengineering (Nibib)	2016-01-01